, Volume 12, Issue 2, pp 132–136 | Cite as

Non-antibiotic prevention of urinary tract infection

  • L. Hagberg
  • H. Leffler
  • C. Svanborg Edén
Sils Maria Symposium


The identification of several glycoconjugates as receptors for attaching bacteria has resulted in optimism regarding the use of receptor analogues in preventing infection. The structure of receptor-active oligosaccharides and the patient groups which might benefit from such treatment are most thoroughly understood for urinary tract infections. Prevention of adhesion and delay or decrease of infection was achieved using oligosaccharides from the globoseries of glycolipids containing Galα1→4Gal. This minimal receptor structure as a free saccharide was, however, not sufficient. It was the intact P, P1 and pk determinants which showed optimal activityin vitro. In addition, protection against experimental UTI results from previous exposure to whole bacteria or isolated antigens. The mechanism(s) of protection and their relevance in clinical UTI remain to be defined.


Public Health Internal Medicine Saccharide Infectious Disease Patient Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Nicht-antibiotische Prävention von Harnwegsinfektionen


Verschiedene Glykokonjugate wurden als Rezeptoren für anheftende Bakterien identifiziert; daher besteht Hoffnung auf die Anwendung von Rezeptoranaloga zur Infektionsverhütung. Die Strukturen der Rezeptor-wirksamen Oligosaccharide und Patientengruppen, die von einer solchen Therapie profitieren könnten, sind für Harnwegsinfektionen sorgfältig erforscht. Mit Oligosacchariden der Globoserie von Glykolipiden, die Galα 1→4Gal enthalten, ist es gelungen, das Anheften zu verhindern und die Infektion zu verzögern oder zu vermindern. Jedoch erwies sich diese minimale Rezeptorstruktur als freies Saccharid als nicht ausreichend.In vitro konnte vielmehr durch die intakten P-, P1- und pk-Determinanten eine optimale Wirkung erzielt werden. Eine Schutzwirkung vor experimenteller Harnwegsinfektion entsteht zusätzlich durch frühere Exposition gegenüber den kompletten Bakterien oder isolierten Antigenen. Auf welche Weise die Protektion zustande kommt und welche Bedeutung sie für klinische Harnwegsinfektionen hat, muß noch geklärt werden.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kunin, C. M., Deutscher, R., Paquin, A. Urinary tract infection in school children: An epidemiologic, clinical and laboratory study. Medicine 43 (1964) 91–130.Google Scholar
  2. 2.
    Winberg, J., Andersson, H. J., Bergström, T., Jacobsson, B., Larsson, H., Lincoln, K. Epidemiology of symptomatic urinary tract infection in childhood. Acta Paediatr. Scand. Suppl. 252 (1974) 1–20.Google Scholar
  3. 3.
    Bergström, T., Lincoln, K., Ørskov, F., Ørskov, I., Winberg, J. Studies of urinary tract infections in infancy and childhood. VIII. Reinfection vs. relapse in recurrent urinary tract infecting organisms. J. Pediatr. 71 (1967) 13–20.Google Scholar
  4. 4.
    Hagberg, L., Engberg, I., Freter, R., Lam, J., Olling, S., Svanborg Edén, C. Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenicEscherichia coli of human origin. Infect. Immun. 40 (1983) 273–283.Google Scholar
  5. 5.
    Korhonen, T. K., Leffler, H., Svanborg Edén, C. Specificity of the binding to epithelial cells, erythrocytes and yeast cells of piliated strains ofEscherichia coli andSalmonella typhimurium. Infect. Immun. 32 (1981) 796–804.Google Scholar
  6. 6.
    Svanborg Edén, C., Eriksson, B., Hanson, L. Å. Adhesion ofEscherichia coli to human uroepithelial cellsin vitro. Infect. Immun. 18 (1977) 767–774.Google Scholar
  7. 7.
    Leffler, H., Svanborg Edén, C. Chemical identification of a glycosphingolipid receptor forEscherichia coli attaching to human urinary tract epithelial cells and agglutinating of human erythrocytes. FEMS Microbiol. Lett. 8 (1980) 127–134.Google Scholar
  8. 8.
    Källenius, G., Möllby, R., Svensson, S. B., Winberg, J., Lundblad, A., Svensson, S. The pk antigen as receptor of pyelonephriticE. coli. FEMS Microbiol. Lett. 7 (1980) 297–302.Google Scholar
  9. 9.
    Duguid, J. P. The function of bacterial fimbriae. Arch. Imm. Ther. Exp. 16 (1968) 173–188.Google Scholar
  10. 10.
    Ørskov, I., Ørskov, F., Birch-Andersen, A. Comparison ofEscherichia coli fimbrial antigen F7 with type 1 fimbriae. Infect. Immun. 27 (1980) 657–666.Google Scholar
  11. 11.
    Marcus, D. M., Naiki, M., Kundu, S. K. Abnormalities in the glycosphingolipid content of human pk and p erythrocytes. Proc. Natl. Acad. Sci. USA 73 (1976) 3263–3267.Google Scholar
  12. 12.
    Kościelak, J., Miller-Podraza, H., Krauze, R., Cedergren, B. Glycolipid composition of blood P erythrocytes. FEBS Lett. 66 (1976) 250–253.Google Scholar
  13. 13.
    Breimer, M. E., Hansson, G. C., Karlsson, K. A., Leffler, H., Pimlott, W., Samuelsson, B. E. Selected ion monitoring of glycosphingolipid mixtures. Identification of several blood group type glycolipids in the small intestine of an individual rabbit. Biomed. Mass. Spectrom. 6 (1979) 231–241.Google Scholar
  14. 14.
    Engvall, E., Perlman, P. Enzyme-linked immunosorbent assay, ELISA III. Quantitation of specific antibodies by enzyme-labelled anti-immunoglobulin in antigen-coated tubes. J. Immunol. 109 (1972) 129–135.Google Scholar
  15. 15.
    Ørskov, I., Ørskov, F. Serology ofEscherichia coli fimbriae. Progr. Allergy 33 (1982) 80–105.Google Scholar
  16. 16.
    Svanborg Edén, C., Fasth, A., Jodal, U. Immunology of urinary tract infection. In:Reeves, D. S., Geddes, A. M. (eds.): Recent advances in infection. Churchill Livingstone, London 1982, pp. 141–162.Google Scholar
  17. 17.
    Hunter, B. W., Akins, L. L., Sanford, J. P. The role of immunity in the pathogenesis of experimental retrograde pyelonephritis. J. Exp. Med. 119 (1964) 869–879.Google Scholar
  18. 18.
    Brooks, S. J. D., Lyons, J. M., Braude, A. I. Immunization against retrograde pyelonephritis. Am. J. Pathol. 74 (1974) 345–354.Google Scholar
  19. 19.
    Uehling, D. T., Mizutani, K., Balish, E. Effect of immunization on bacterial adherence to urothelium. Invest. Urol. 16 (1978) 145–147.Google Scholar
  20. 20.
    Kaijser, B., Larsson, P., Olling, S. Protection against ascendingEscherichia coli pyelonephritis in rats and significance of local immunity. Infect. Immun. 20 (1978) 78–81.Google Scholar
  21. 21.
    Kaijser, B., Larsson, P., Olling, S., Schneerson, R. Protection against acute ascending pyelonephritis caused byEscherichia coli in rats, conjugated to bovine serum albumin. Infect. Immun. 39 (1983) 142–146.Google Scholar
  22. 22.
    Layton, G. T., Smithyman, A. M. The effects of oral and combined parenteral/oral immunization against an experimentalEscherichia coli urinary tract infection in mice. Clin. Exp. Immunol. 54 (1983) 305–312.Google Scholar
  23. 23.
    Silverblatt, F., Cohen, S. Antipili antibody affords protection against experimental ascending pyelonephritis. J. Clin. Invest. 64 (1979) 333–336.Google Scholar
  24. 24.
    Svanborg Edén, C., Briles, D., Hagberg, L., McGhee, J., Michalec, S. Genetic factors in host resistance to urinary tract infections. Infection 12 (1984) 118–122.Google Scholar
  25. 25.
    Svanborg Edén, C., Eriksson, B., Hanson, L. Å., Jodal, U., Kaijser, B., Lidin-Janson, G., Lindberg, U., Olling, S. Adhesion to normal human uroepithelial cells ofEscherichia coli from children with various forms of urinary tract infection. J. Pediatr. 93 (1978) 398–403.Google Scholar
  26. 26.
    Freter, R. Studies of the mechanism of action of intestinal antibody in experimental cholera. Tex. Rep. Biol. Med. 27 Suppl. 1 (1969) 299–316.Google Scholar
  27. 27.
    Svanborg Edén, C., Svennerholm, A.-M. Secretory IgA and IgG prevent adhesion ofEscherichia coli to human urinary tract epithelial cells. Infect. Immun. 22 (1978) 790–797.Google Scholar
  28. 28.
    Svanborg Edén, C., Andersson, B., Leffler, H., Magnusson, G.: Binding to glycoconjugate receptors explaining the adhesion ofE. coli andS. pneumoniae. J. Dental Res. (in print).Google Scholar
  29. 29.
    Williams, R. C., Gibbons, R. J. Inhibition of bacterial adherence by secretory immunoglobulin A: A mechanism of antigenic disposal. Science 177 (1972) 697–699.Google Scholar
  30. 30.
    Svanborg Edén, C., Andersson, B., Hagberg, L., Hanson, L. Å., Lomberg, H., Leffler, H., Magnusson, G., Noori, G., Dahmén, J., Söderström, T. Receptor analogues and anti-pili antibodies as inhibitors of bacterial attachmentin vivo andin vitro. Proc. N. Y. Acad. Sci. 409 (1983) 580–592.Google Scholar
  31. 31.
    Svanborg Edén, C., Freter, R., Hagberg, L., Hull, R., Hull, S., Leffler, H., Schoolnik, G. Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue. Nature (London) 298 (1982) 560–562.Google Scholar
  32. 32.
    Källenius, G., Svensson, S. B., Hultberg, H., Möllby, R., Winberg, J., Roberts, J. A. P-fimbriae of pyelonephritogenicEscherichia coli: Significance for reflux and renal scarring. Infection 11 (1983) 73–76.Google Scholar
  33. 33.
    Svanborg Edén, C., Fasth, A., Hagberg, L., Hanson, L. Å., Korhonen, T., Leffler, H. Host interaction withEscherichia coli in the urinary tract. In:Robbins, J. B., Hill, J. C., Sadoff, J. C. (eds.): Seminars in infectious disease. Thieme Stratton Inc., New York 1982, pp. 113–131.Google Scholar
  34. 34.
    Svanborg Edén, C., Bjursten, L. M., Hagberg, L., Hull, R., Hull, S., Jodal, U., Leffler, H., Lomberg, H.: New aspects on pathogenesis and treatment of urinary tract infections, in relation to bacterial adherence. In:Losse, H., Lison, A. E. (eds.): Georg Thieme Verlag, Stuttgart (in print).Google Scholar
  35. 35.
    Leffler, H., Svanborg Edén, C. Glycolipid receptors for uropathogenicE. coli binding to human erythrocytes and uroepithelial cells. Infect. Immun. 34 (1981) 930–939.Google Scholar
  36. 36.
    Källenius, G., Möllby, R., Svensson, S. B., Helin, I., Hultberg, H., Cedergren, B., Winberg, J. Occurrence of P-fimbriatedEscherichia coli in urinary tract infections. Lancet II (1981) 1369–1372.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1984

Authors and Affiliations

  • L. Hagberg
    • 1
  • H. Leffler
    • 2
  • C. Svanborg Edén
    • 1
  1. 1.Department of Clinical ImmunologyUniversity of Göteborg Medical SchoolGöteborg
  2. 2.Department of Medical and Physiological BiochemistryUniversity of Göteborg Medical SchoolGöteborg

Personalised recommendations